p53‐Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study

p53 activation is a primary mechanism underlying pathological responses to DNA damaging agents such as chemotherapy and radiotherapy. Our recent animal studies showed that low dose arsenic (LDA)‐induced transient p53 inhibition selectively protected normal tissues from chemotherapy‐induced toxicity....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Principais autores: Ha, Chul S., Michalek, Joel E., Elledge, Richard, Kelly, Kevin R., Ganapathy, Suthakar, Su, Hang, Jenkins, Carol A., Argiris, Athanassios, Swords, Ronan, Eng, Tony Y., Karnad, Anand, Crownover, Richard L., Swanson, Gregory P., Goros, Martin, Pollock, Brad H., Yuan, Zhi-Min
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4597306/
https://ncbi.nlm.nih.gov/pubmed/26440706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.09.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados